Cell Therapeutics Inc. (CTIC) Reports In-Line Q4 Loss of $0.20/Sh

February 28, 2013 5:35 PM EST
Get Alerts CTIC Hot Sheet
Trade CTIC Now!
Join SI Premium – FREE
Cell Therapeutics Inc. (NASDAQ: CTIC) reported Q4 EPS of ($0.20), in-line with the analyst estimate of ($0.20).

For 2013, loss from operations is expected to be approximately $60 to $65 million, excluding non-cash stock-based compensation expense.

For earnings history and earnings-related data on Cell Therapeutics Inc. (CTIC) click here.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories


Related Entities


Add Your Comment